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Transplantation Unit, St George’s University Hospitals NHS Foundation Trust, London, UKIntroduction: There is paucity of literature comparing outcomes of kidney transplant patients with COVID-
19 to that of dialysis and waitlisted patients. This report describes our data, provides comparative analysis,
together with a meta-analysis of published studies, and describes our protocols to restart the transplant
program.
Methods: Data were analyzed on kidney transplant, dialysis, and waitlisted patients tested positive for
SARS-CoV-2 (nasopharyngeal swab polymerase chain reaction [PCR] test) between March 1, 2020, and
June 30, 2020, together with a meta-analysis of 16 studies.
Results: Twenty-three of 1494 kidney transplant patients tested positive for SARS-CoV-2 compared with
123 of 1278 hemodialysis patients (1.5% vs. 9.6%, P < 0.001) and 12 of 253 waitlisted patients (1.5% vs.
4.7%, P ¼ 0.002). Nineteen patients required hospital admission, of whom 6 died and 13 developed AKI.
The overall case fatality ratio was 26.1% compared with patients on hemodialysis (27.6%, P ¼ 0.99) and
waitlisted patients (8.3%, P ¼ 0.38). Within our entire cohort, 0.4% of transplant patients died compared
with 0.4% of waitlisted patients and 2.7% of hemodialysis patients. Patients who died were older (alive
[median age 71 years] vs. dead [median age 59 years], P ¼ 0.01).
In a meta-analysis of 16 studies, including ours, the pooled case fatality ratio was 24% (95% confidence
interval [CI] 19%, 28%); AKI proportion in 10 studies was 50% (95% CI 45%, 56%), with some evidence
against no heterogeneity between studies (P ¼ 0.02).
Conclusions: From our cohort of transplant patients, a significantly lower proportion of patients contracted
COVID-19 compared with waitlisted and dialysis patients. The case fatality ratio was comparable to that of
the dialysis cohort and to a pooled case fatality ratio from a meta-analysis of 16 studies. The pooled AKI
ratio in the meta-analysis was similar to our results.
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ARS-CoV-2, the virus that causes COVID-19, con-
tinues to cause significant mortality and morbidity
across the world as the pandemic evolves. As of July
27, 2020, a total of 300,111 people had tested positive
for the virus in the United Kingdom and, of those
tested positive, across all settings, 45,312 have died.
The disease is primarily pulmonary, but involvementspondence: Debasish Banerjee, Renal and Transplantation
Grosvenor Wing, Room 2.113, St George’s University Hos-
NHS Foundation Trust, Blackshaw Road, Tooting, London,
W17 0QT. E-mail: Debasish.Banerjee@stgeorges.nhs.uk
ved 27 August 2020; revised 20 November 2020; accepted 10
ber 2020; published online 19 December 2020of other organs, including the kidneys and heart, dur-
ing the course of illness is now well recognized. Kidney
transplant recipients, because of their immunosuppres-
sive burden and underlying comorbidities, are thought
to be at higher risk of acquiring the infection as well as
developing severe disease requiring hospitalization.
We recently reported our initial experience of 7 renal
transplant patients from 3 south London hospitals: 2
of 7 patients were managed at home and 1 patient
died.1 All patients were managed with reduction of
immunosuppression with no specific antiviral or anti-
inflammatory therapies. In the same journal edition,
Alberici et al. published their early experience of 20
kidney transplant patients admitted with SARS CoV-2Kidney International Reports (2021) 6, 574–585
M Phanish et al.: COVID-19 in Kidney Transplant CLINICAL RESEARCHpneumonia in which they described a 25% mortality in
spite of additional treatment with various drugs that
included lopinavir/ritonavir, hydroxychloroquine,
dexamethasone, and tocilizumab.2 Since these early re-
ports, there have been several further reports of
COVID-19 in kidney transplant patients describing
overall case fatality ratios of 10% to 38% and 50%
to 65% for patients requiring invasive ventilation.3–19
We and others have advocated for immunosup-
pression reduction as a primary therapeutic strategy
for hospitalized kidney transplant patients with
COVID-19 pneumonia, with cessation of anti-
proliferative agents (mycophenolate mofetil/azathio-
prine) and continuation of calcineurin inhibitors either
at the same or reduced dose depending on severity of
disease along with continuation of corticosteroids.1–3,6
In this report, we describe 23 kidney transplant
patients tested positive for SARS-CoV-2 from 2 tertiary
care renal centers from South London Renal transplant
Network, United Kingdom. This includes follow-up
data on 5 patients described in our previous report.
The aim of this analysis was to further characterize
SARS-CoV-2–infected transplant patients, describe
their management and outcome, and compare the pro-
portion of infections and case fatality ratios in trans-
plant patients with waitlisted and the total cohort of
dialysis patients. In addition, we have performed meta-
analyses on 15 published studies on COVID-19 in
kidney transplant patients in addition to ours to derive
case fatality–acute kidney injury (AKI) ratios in hos-
pitalized kidney transplant patients with COVID-19.METHODS
Data were collected on all kidney transplant recipients
tested positive for SARS-CoV-2 between March 1, 2020,
and June 30, 2020 (first wave of COVID-19 in the
United Kingdom) and followed until October 15, 2020.
The data collected included demographics, clinical and
laboratory parameters, and outcomes. In addition, we
collected data on dialysis patients that included all the
patients on dialysis and those on the transplant wait-
list. Data were collected as part of routine clinical
processes and downloaded for the study from the
electronic patient records. The study was approved by
NHS Research Ethics Committee 20/SW/0077 and Heath
Research Authority IRAS 283130.
Continuous variables were summarized by their
means, medians, standard deviations, interquartile
ranges (IQRs) and limits; categorical data were sum-
marized as proportions. Two-sample independent tests
tailored to the nature of the variables were used to test
the null hypothesis of no difference between transplant
patients and those on the waiting list. A 22
Kidney International Reports (2021) 6, 574–585contingency table and Fisher exact tests were employed
to assess the effect of dual vs. triple immunosuppres-
sion on the outcome of death.
Meta-analyses were performed to derive pooled
proportions of deaths, AKI, and AKI stage 3 among
positive patients using the available data from 15
published studies and our data. Using the keywords
COVID-19, kidney transplant, mortality, and AKI for a
PubMed search, we analyzed the outcomes for studies
published between May 15, 2020, and October 20,
2020. Among 157 returns, we selected 15 studies that
included at least 10 patients reporting mortality of
hospitalized patients and/or AKI.2,3,5,8–19 Methods
associated with analyses of proportions specific to
binomial data allow computation of exact binomials
and score test–based CIs. They also use appropriate
methods for dealing with proportions close to or at the
margins where the normal approximation procedures
often break down, by use of the binomial distribution
to model the within-study variability or by allowing
Freeman-Tukey double arcsine transformation to sta-
bilize the variances. (We used Metaprop command
implemented in Stata, release 16 [StataCorp LLC, Col-
lege Station, TX].)RESULTS
Clinical Characteristics
Twenty-three transplant patients tested positive for
SARS-CoV-2 during the study period from a total
cohort of 1494 kidney transplant recipients under
follow-up in 2 renal centers (1.5% of total transplant
cohort) (Table 1). Four were managed at home and 19
patients required hospitalization. The mean age was
629.2 years and the median age 62 years (IQR 55–69
years), compared with the median age of 51 years of the
overall transplant cohort. There were 17 male and 6
female patients. Six (26%) patients were of black
ethnicity, 9 white (39.1%), 4 South Asian (21.7%), 1
East Asian, 1 Hispanic, and 2 other. In comparison, the
ethnicity of our entire transplant cohort as reported
previously was black, 7.7%; white, 73.8%; and South
Asian, 15.4%.7 Twenty-two patients had hypertension,
2 had a history of cancer, 8 had diabetes, and 1 had
HIV. The 19 hospitalized patients had a mean age of
64.2  8.7 years and a median age of 64 years (IQR 59–
72 years). The median follow-up period was 183 days
(range 169–199 days, IQR 173–192 days). The median
transplant vintage (from transplant date to date of
positive swab) was 1686 days (4.6 years; range 47–
12,054 days, IQR 273–5326 days). Three patients (2
hospitalized, 1 managed at home) were within 3 months
since receiving transplant (53 days, 56 days, and 47
days), 3 were between 3 and 12 months since their575
Table 1. Patient Demographics, Comorbidities, Immunosuppressive Drugs, Hospital Management (Critical Care Admission,
Type of Respiratory Support, and Renal Replacement Therapy)
Variable / Summary Type or Category All (N [ 23) Alive (n [ 17; 73.9%) Died (n [ 6; 26.1%) Two-Sample Independent Test (P Value)
Age, yr
Mean (SD) 62 (9.2) 59.2 (8.2) 70.5 (6.8) 0.01
Median (Q1-Q3) 62 (55-69) 59 (54-64) 71 (68-76)
Range 45-78 45-73 59-78
Gender
Female 6 (26) 5 (29) 1 (17) 0.99
Male 17 (74) 12 (71) 5 (83)
Ethnicity
Black 6 (26.1) 4 (23.5) 2 (33.3) 0.615
East Asian 1 (4.4) 1 (5.9) 0 (0)
Other 2 (8.7) 1 (5.9) 1 (16.7)
South Asian 5 (21.7) 3 (17.7) 2 (33.3)
White 9 (39.1) 8 (47.1) 1 (16.7)
Immunosuppressive drugs
2 14 (61) 12 (71) 2 (33.3) 0.162
3 9 (39) 5 (29) 4 (66.6)
Transplant type
DBD 17 (73.9) 12 (70.6) 5 (83.3) 0.99
DCD 4 (17.4) 3 (17.7) 1 (16.7)
Living Donor 2 (8.7) 2 (11.8) 0 (0)
Tacrolimus, yes 21 (91.3) 15 (88.2) 6 (100) 0.99
Cyclosporine, yes 1 (4.4) 1 (5.9) 0 (0) 0.99
Azathioprine, yes 2 (8.7) 2 (11.8) 0 (0) 0.99
MMF, yes 13 (56.6) 9 (52.9) 4 (66.7) 0.66
Prednisolone, yes 16 (69.6) 11 (64.7) 5 (83.3) 0.621
Cancer
Yes 2 (8.7) 1 (5.9) 1 (16.7) 0.521
Missing 3 (13) 3 (17.7) 0 (0)
Diabetes, yes 8 (34.8) 4 (23.5) 4 (66.7) 0.131
Chronic lung disease
Yes 0 (0) 0 (0) 0 (0) NA
Missing 3 (13) 3 (17.7) 0 (0)
Hypertension, yes 21 (91.3) 15 (88.2) 6 (100) 0.99
Platelets
Mean (SD) 213 (50.1) 221.1 (53) 193.8 (39.9) 0.30
Median (Q1-Q3) 206 (178-238.5) 213.5 (186-251) 193 (157-230)
Range 144-337 157-337 144-246
Missing 3 (13) 3 (17.6) 0 (0)
White blood cell count
Mean (SD) 6.6 (1.9) 6.4 (1.9) 7.1 (2.0) 0.563
Median (Q1-Q3) 6.6 (5.3-7.4) 6.5 (5.1-7.3) 6.7 (6.4-9.1)
Range 3.2-10.3 3.2-10.3 3.9-9.5
Missing 3 (13) 3 (17.6) 0 (0)
Baseline lymphocyte count
Mean (SD) 1.5 (0.9) 1.7 (0.9) 1.2 (0.7) 0.303
Median (Q1-Q3) 1.4 (1.1-1.9) 1.6 (1.2-2) 1.1 (0.5-1.7)
Range 0.3-4.2 0.3-4.2 0.4-2.3
Missing 3 (13) 3 (17.6) 0 (0)
Hemoglobin on admission
Mean (SD) 113.1 (20.6) 115.6 (22.7) 107.2 (14.5) 0.283
Median (Q1-Q3) 116.5 (99-130) 117.5 (101-131) 105 (97-109)
Range 67-149 67-149 93-134
Missing 3 (13) 3 (17.6) 0 (0)
Lymphocyte nadir during admission
Mean (SD) 0.7 (0.9) 0.8 (1) 0.5 (0.4) 0.334
Median (Q1-Q3) 0.4 (0.2-0.8) 0.4 (0.2-0.8) 0.25 (0.2-0.7)
Range 0.2-4.1 0.2-4.1 0.2-1.1
Missing 3 (13) 3 (17.6) 0 (0)
Highest ferritin during admission
Mean (SD) 1691.7 (1901.5) 1598.1 (2004.4) 1949 (1833.2) 0.896
Median (Q1-Q3) 781 (544-2469) 781 (549-1320) 1506 (503-3395)
Range 462-6959 538-6959 462-4321
(Continued on following page)
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Table 1. (Continued) Patient Demographics, Comorbidities, Immunosuppressive Drugs, Hospital Management (Critical Care Admission,
Type of Respiratory Support, and Renal Replacement Therapy)
Variable / Summary Type or Category All (N [ 23) Alive (n [ 17; 73.9%) Died (n [ 6; 26.1%) Two-Sample Independent Test (P Value)
Missing 8 (35) 6 (35) 2 (33)
Highest CRP during admission
Mean (SD) 186.7 (106.1) 161.1 (83.4) 237.8 (135.3) 0.223
Median (Q1-Q3) 178.5 (122-230) 160.5 (114.5-212) 217 (147-233)
Range 31-497 31-320 116-497
Missing 5 (22) 5 (29) 0 (0)
RRT during admission
No 15 (78.9) 12 (85.7) 3 (60) 0.272
Yes 4 (21.1) 2 (14.3) 2 (40)
ITU admission
No 10 (52.6) 9 (69.2) 1 (16.7) 0.05
Yes 9 (47.4) 4 (30.8) 5 (83.3)
On ACEi/ARB
No 9 (39.1) 7 (41.2) 2 (33.3) 0.99
Yes 10 (43.5) 7 (41.2) 3 (50)
Missing 4 (17.4) 3 (17.7) 1 (16.7)
Breathing support
Nasal cannula/mask 10 (52.6) 9 (69.2) 1 (16.7) 0.045
Invasive ventilation 6 (31.6) 3 (23.1) 3 (50)
NIV/HFNC 3 (15.8) 1 (7.7) 2 (33.3)
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRP, C-reactive protein; DBD, deceased brain donor; DCD, deceased cardiac donor; HFNC, high-flow
nasal cannula; ITU, intensive therapy unit; MMF, mycophenolate mofetil; NIV, noninvasive ventilation; Q1-Q3, quartile 1 to quartile 3; RRT, renal replacement therapy; SD, standard
deviation.
Unless otherwise noted, values are n (%). Data for hospitalized patients are for 19 patients. Rest of the data are for 23 patients. Age, requirement of respiratory support, and intensive
care unit admission were significantly different between the 2 groups (Alive vs. Died). P values in bold indicate significance.
M Phanish et al.: COVID-19 in Kidney Transplant CLINICAL RESEARCHtransplant, and the rest (17) had received their trans-
plant >12 months ago. None of the patients who died
had their transplant within the previous 6 months.
All patients had received basiliximab induction.
Fifteen patients, including 4 managed at home, were on
dual maintenance immunosuppression, and 8 patients
were on triple immunosuppression. Two of 19 hospi-
talized patients had received their transplant in
February 2020.
Management
All hospitalized patients were managed with immu-
nosuppression reduction, and antiproliferative agents
(mycophenolate mofetil/azathioprine) were stopped on
admission in all the patients (n¼19). Tacrolimus dose
was reduced in mild to moderate cases (n¼11) and
stopped in severe cases where there was progressive
clinical and radiologic deterioration (n¼8). Predniso-
lone dose was either unchanged (n¼3) or increased
(n¼13) in all cases. Some of the patients were
recruited into the RECOVERY trial (Randomised
Evaluation of COVID-19 therapy, www.recoverytrial.
net). As a part of this trial, 2 patients received
hydroxychloroquine and 1 received dexamethasone.
In addition, 2 patients received tocilizumab. Of the 4
patients managed at home, 1 patient had his myco-
phenolate mofetil dose reduced by 50% with increase
back to the baseline dose after 2 weeks, and the
remaining 3 patients were managed without any
change to immunosuppression (Table 2).Kidney International Reports (2021) 6, 574–585All patients who had tacrolimus dose reduced had
the dose progressively increased such that by 2 weeks
postdischarge, the levels were in a therapeutic range (5-
8 ng/ml). Mycophenolate mofetil was reintroduced
around 2-3 weeks postdischarge provided patients
were well with no fever or other symptoms of COVID-
19 for at least 3 days and had a normal C-reactive
protein level.
Patient demographics, laboratory parameters, and
clinical outcomes are summarized in Table 1. Age,
admission to intensive care unit, and type of respira-
tory support required were the only variables signifi-
cantly different in patients who died compared with
those discharged home. Patients who died were
significantly older (59.28.2 vs. 70.56.8 years,
P¼0.01) and required more ventilatory support
(P¼0.04). There were no significant differences be-
tween the 2 groups (living vs. died) with regard to
comorbidities, peak ferritin levels, C-reactive protein,
baseline lymphocyte count, or lowest lymphocyte
count during admission (Table 1).Outcome of Infected Patients
Duration of hospital stay, respiratory support, AKI,
renal replacement therapy (RRT), and outcome of hos-
pitalized patients (n¼19) are described in Table 2. Six
of the 19 (31.57%) hospitalized patients died (Table 2).
Of the total cohort of 1494 transplant patients, 6 pa-
tients died, which represents 0.4% of the total cohort.577








Yes/No Comments and Outcome
1 12 Nasal cannula and mask Renal ward Y, St 3 Y (Intermittent HD) Discharged home, alive to date, graft failed,
transplant nephrectomy—90 d postdischarge
2 12 Intubation and ventilation Intensive (critical) care unit Y, St 3 Y (CVVHDF) Died
3 5 Intubation and ventilation Intensive (critical) care unit Y, St 2 N Discharged home, alive to date with functioning graft,
renal function back to baseline
4 7 Nasal cannula Medical ward, palliative care Y, St 3 N Died
5 12 HFNC, NIV, intubation and ventilation Renal ward, respiratory ward,
intensive (critical) care unit
Y, St 2 N Died
6 5 Nasal cannula and venturi mask Renal ward Y, St 3 N Discharged home, alive to date, poorly functioning graft
7 8 Nasal cannula Renal ward N N Discharged Home, alive to date, functioning graft
8 7 Nasal cannula and venturi mask Renal ward Y, St 2 N Discharged home, alive to date, functioning graft, renal
function back to baseline
9 80 NIV, intubation, and ventilation (57 d of
invasive ventilation)
Renal ward, intensive (critical) care
unit
Y, St 3 Y (CVVHDF and
intermittent HD)
Discharged home, alive to date, graft failed
10 13 Nasal cannula Renal ward Y, St 2 N Discharged home, alive to date, functioning graft, renal
function back to baseline
11 4 Nasal cannula High-dependency unit N N Discharged Home, Alive to date, functioning Graft
12 5 Nasal cannula Renal ward Y, St 1 N Discharged home, Alive to date, functioning Graft, renal
function back to baseline
13 5 NIV ITU Y, St 1 No Died
14 4 Nasal cannula/venturi mask High-dependency unit N N Discharged home, alive to date, functioning graft
15 5 HFNC (refused intubation) ITU Y, St 2 N Died
16 11 NIV ITU N N Discharged home, alive to date, functioning graft
17 23 Intubated and ventilated ITU N N Discharged home, alive to date, functioning graft
18 2 Nasal cannula Ward N N Discharged home, alive to date, functioning graft
19 21 Intubated and ventilated ITU Y, St 3 Y Died
20 0 None Home N N Alive, no change in immunosuppression, no graft
dysfunction
21 0 None Home N N Alive, MMF dose halved, No graft dysfunction
22 0 None Home N N Alive, no change in immunosuppression, no graft
dysfunction
23 0 None Home N N Alive, no change in immunosuppression, no graft
dysfunction
AKI, acute kidney injury; CVVHDF, continuous venovenous hemodiafiltration; HD, hemodialysis; HFNC, high-flow nasal cannula; ITU, intensive therapy unit; N, no; NIV, noninvasive
ventilation; RRT, renal replacement therapy; St, stage (of AKI); Y, yes.
CLINICAL RESEARCH M Phanish et al.: COVID-19 in Kidney TransplantTwelve of 14 (85.7%) patients on dual immuno-
suppression survived and 2 (14.3%) died. Of the 9
patients on triple immunosuppression, 5 (55.6%) sur-
vived and 4 (44.4%) died. Although nonsignificant
(P¼0.16), the relative risk of death on triple immuno-
suppression was 1.54 (95% CI 0.91, 3.28) and the odds
ratio 4.8 (95% CI 0.71, 29.3) (Table 3). There was no
difference in the proportion of patients on maintenance
steroids between the 2 groups (survived vs. died)
(Table 1).
Among 6 patients who died, 1 patient was white, 2
black, 2 South Asian, and 1 other. The ethnicity was
not significantly different between the 2 groupsTable 3. The Effect of Baseline Dual vs. Triple Immunosuppression on M
Immunosuppression (Whole Cohort) Alive, n (%) Died, n (%)
Dual (n ¼ 14) 12 (85.7) 2 (14.3)
Triple (n ¼ 9) 5 (55.6) 4 (44.4)
CI, confidence interval; OR, odds ratio; RR, relative risk.
RR of death in patients on triple immunosuppression was 1.54, but there was no statistical dif
578(survived and died), but this may be due to the small
sample size. All patients who died had hypertension,
and 4 had diabetes.
Respiratory support
Of 19 hospitalized patients, 3 were managed on high-
flow nasal cannula or noninvasive ventilation, 6
(31%) were intubated and ventilated, and the remain-
ing 10 were managed with oxygen delivered through
nasal cannula or venturi mask (Tables 1 and 2). Of the 6
intubated and ventilated patients, 3 (50%) died. Of the
3 other patients who were discharged home, 2 had a
functioning graft and 1 remained on dialysis. The pa-
tient who was discharged on dialysis had poor graftortality (n¼23)
P RR (95% CI) of Death OR (95% CI)
0.16 1.54 (0.91-3.28) 4.8 (0.71-29.3)
ference between the groups (Fisher exact test).
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Table 4. Proportions of Infections, Deaths in Transplant, Waitlisted,












Total cohort (n) 1494 253 1278 170
COVID-19–positive (n) 23 12 123 8
Percentage of COVID-19–
positive all patients in the
cohort
1.5 4.7 9.6 4.7
Deaths (n) 6 1 34 6
Case fatality ratio
(% of deaths among the
COVID-19–positive)
26.1 8.3 27.6 75.0
Percentage of deaths (% of
deaths among all patients
in the cohort)
0.4 0.4 2.7 3.5
Proportions of infections and case fatality ratio of transplant patients (1) compared to
patients on transplant waitlist (2), hemodialysis (3), and peritoneal dialysis patients (4).
M Phanish et al.: COVID-19 in Kidney Transplant CLINICAL RESEARCHfunction before he had COVID-19 and was on hemo-
dialysis preadmission. He was ventilated for a pro-
longed period of 57 days.
AKI
Thirteen of 23 patients (57%) developed AKI; 11 pa-
tients had stage 2 or 3 AKI (stage 2: 5 patients, stage 3:
6 patients) and 2 patients had stage 1 AKI. Four patients
needed RRT (hemodialysis or continuous venovenous
hemodiafiltration) (Tables 1 and 2). AKI resolved in all
but 3 patients. These 3 patients in whom transplant
kidney function failed to recover had poor baseline
kidney function with a Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation-based
estimated glomerular filtration rate of <20 ml/min per
1.73 m2. None of the patients underwent percutaneous
kidney biopsy. Two patients continued on hemodial-
ysis, and 1 was discharged with CKD stage 5 and
commenced hemodialysis 5 months postdischarge. Of
the 2 patients who have remained on hemodialysis
postdischarge, 1 (patient 1 in Table 2) underwent
transplant nephrectomy 3 months postdischarge as a
result of severe rejection (clinical diagnosis). His nose
and throat swabs for SARS-CoV-2 PCR both before and
during this admission were negative. He made good
recovery from surgery and is currently on outpatient
hemodialysis. His histology of kidney post-
nephrectomy revealed severe vascular rejection, withTable 5. Comparisons of the proportions of Infections and Deaths in Tran
1 vs. 2
Proportion of COVID-19–positive among all 0.002
Case fatality ratio (% of deaths among the COVID-19–positive patients) 0.380
There was a significant difference in infection risk in transplant patients compared to patients on
difference in case fatality ratio between transplant patients and other groups.
Comparisons were performed between aggregated proportions. Only P values lower than 0.05/
multiple comparisons.
aComparison groups: (1) transplant patients; (2) patients on transplant waitlist; (3) hemodialysi
Kidney International Reports (2021) 6, 574–585widespread cortical infarctions and a thrombus in the
main transplant artery.
At follow-up till October 15, 2020 (median follow-up
of 183 days), all discharged patients and those managed
at home (n¼17) have remained well with no read-
missions apart from the patient described above. Three
patients have lost their graft function (all with baseline
estimated glomerular filtration rate <20 ml/min per
1.73 m2).
Eight of 9 hospitalized patients discharged home
(from 1 center) with baseline positive nasopharyngeal
swab for SARS-CoV-2 PCR were reswabbed 3-4 weeks
postdischarge. All of them had cleared the virus, as
shown by negative nose and throat swab results.
Comparisons With Dialysis Cohort
and Waitlisted Patients
Twenty-three from a cohort of 1494 kidney transplant
patients were tested positive for SARS-CoV-2 compared
with 123 of 1278 hemodialysis patients (1.5% vs. 9.6%,
P < 0.001), 12 of 253 waitlisted patients (1.5% vs.
4.7%, P ¼ 0.002), and 8 of 170 peritoneal dialysis pa-
tients (1.5% vs. 4.7%, P ¼ 0.01) (Tables 4 and 5). The
case fatality ratio was 26.1% for transplant patients,
8.3% for waitlisted patients, 27.6% for hemodialysis
patients, and 75.0% for peritoneal dialysis patients.
There was no statistically significant difference in case
fatality ratio of transplant patients compared with
waitlisted patients, hemodialysis patients, and perito-
neal dialysis patients (Tables 4 and 5).
Meta-analyses
We performed meta-analyses of 15 published studies
and our data to derive a pooled estimate of case fatality
ratio (of hospitalized patients) and AKI in kidney
transplant patients who tested positive for SARS-CoV-
2, including a recent publication of TANGO interna-
tional consortium.2,3,5,8–19 The total number of hospi-
talized patients included in these studies were 871. The
pooled case fatality ratio was 24% (95% CI 19%, 28%).
The variability in the effect size attributable to
between-study heterogeneity was moderate (I2 ¼
51.5%), consistent with some evidence against the null
hypothesis stating no heterogeneity between studiessplant, Waitlisted, Hemodialysis, and Peritoneal Dialysis Patients
Group Comparisons (as in Table 4)a
1 vs. 3 1 vs. 4 2 vs. 3 2 vs. 4 3 vs. 4
<0.001 0.01 0.011 0.999 0.033
0.999 0.032 0.185 0.004 0.010
waitlist and hemodialysis (1 vs. 2, P ¼ 0.002, 1 vs. 3, P < 0.001). There was no significant
12 ¼ 0.0042 are considered significant (shown in bold) due to Bonferroni correction for




Figure 1. Meta-analyses of COVID-19 in transplant patients: case fatality ratio. (a) The pooled case fatality ratio was 24% (95% CI 19%, 28%).
There was moderate heterogeneity between the studies (I2 ¼ 51.5% [variation in effect size (ES) attributable to heterogeneity], heterogeneity
c2 ¼ 30.90 [df ¼ 15], P ¼ 0.01). The New York Montefiore 2 Study—the third most influential in this analysis—exhibited a case fatality ratio of
38% (95% CI 29%, 48%), well above the pooled estimate of 24% (95% CI 19%, 28%). (b) We then analyzed 14 studies excluding this study, and
with this analysis, the I2 drops to 34.3% with a P value ¼ 0.09, consistent with the null hypothesis of not much heterogeneity between studies.
The pooled case fatality ratio in this analysis was 22% (95% CI 18%, 27%).
CLINICAL RESEARCH M Phanish et al.: COVID-19 in Kidney Transplant(P ¼ 0.01) (Figure 1a). The Montefiore 2 Study18—the
third most influential in this analysis—exhibited a case
fatality ratio of 38% (95% CI 29%, 48%), well above580the pooled estimate of 24% (95% CI 19%, 28%).
Excluding this study, the I2 drops to 34.3% with a P
value of 0.09, indicating consistency with theKidney International Reports (2021) 6, 574–585
a
b
Figure 2. Meta-analyses of COVID-19 in transplant patients: (a) AKI, all stages. The pooled proportion of AKI was 50% (95% CI 45%, 56%). There
was no significant heterogeneity between the studies, c2 ¼ 11.02 (df ¼ 9), P ¼ 0.27; I2 (variation in effect size [ES] attributable to
heterogeneity) ¼ 18.37%. Therefore, the pooled proportion of AKI is 50% (95% CI 45%, 56%). (b, c) AKI, stage 3 / RRT requirement. The pooled
proportion of severe AKI (stage 3 / requiring RRT) was 18% (95% CI 12%, 25%) (b). However, there was a significant heterogeneity: I2 ¼ 66.27%,
P < 0.001. Reanalysis after removal of the Bologna study that showed a high stage 3 AKI percentage of 45% yielded results with pooled stage 3 /
RRT-requiring AKI estimate of 16% (95% CI 10%, 22%) but the heterogeneity, although improved, remained significant, with I2 ¼ 56.96%, P < 0.02
(c). Therefore, it appears from these analyses that the pooled proportion of severe AKI is 16% to 18%.
M Phanish et al.: COVID-19 in Kidney Transplant CLINICAL RESEARCHmagnitude of I2 and with the null hypothesis of not
much heterogeneity between studies. The pooled case
fatality ratio in this analysis was 22% (95% CI 18%,
27%), which was very close to our first analysis. Given
the size and hence the precision of estimate in the
Montefiore 2 Study (n¼111), we opted to include all
Kidney International Reports (2021) 6, 574–585studies and provide evidence that the pooled case fa-
tality ratio of hospitalized kidney transplant patients
with COVID-19 is 24% (95% CI 19%, 28%).
The analyses of AKI included 10 studies that re-
ported AKI. The pooled proportion of AKI was 50%
(95% CI 45%, 56%). There was no evidence to suggest581
c
Figure 2. (Continued)
CLINICAL RESEARCH M Phanish et al.: COVID-19 in Kidney Transplantheterogeneity between the studies, P ¼ 0.27, and
therefore, the data estimate that 50% (95% CI 45%,
56%) of kidney transplant patients with COVID-19
develop AKI (Figure 2a). We also separately analyzed
the pooled proportion of severe AKI (stage 3 AKI or
those requiring RRT). This analysis showed a pooled
proportion of stage 3 AKI of 18% (95% CI 12%, 25%)
(Figure 2b). However, there was evidence for presence
of significant heterogeneity between studies (P <
0.001). Reanalysis after removal of the Bologna study
showed that the high stage 3 AKI percentage of 45%
yielded results with a pooled stage 3 / RRT–requiring
AKI estimate of 16% (95% CI 10%, 22%), although
the evidence against no heterogeneity between studies
remained significant (P ¼ 0.02) with I2 ¼ 56.96%
(Figure 2c).DISCUSSION
In this report, we have described 23 kidney transplant
recipients who tested positive for SARS-CoV-2 between
March 1, 2020, and June 30, 2020 (this includes the
entire period of the first surge of COVID-19 in London)
with a median follow-up of 183 days. Nineteen were
hospitalized and 4 managed at home, and 6 patients
died (overall case fatality ratio of 26%, for hospitalized
patients 31.6%). Six patients required intubation and
ventilation, among whom 3 died (50% mortality in
ventilated patients). Age and requirement of intensive
care unit admission and respiratory support (noninva-
sive or invasive ventilation) were significantly different
in patients who died compared with those who582survived. In the meta-analysis of 16 available reports
including ours, the pooled case fatality ratio for hos-
pitalized transplant patients with COVID-19 was 24%
(95% CI 19%, 28%), pooled proportion of AKI (all
stages) was 50% (95% CI 45%, 56%) and that of AKI
stage 3 / requiring RRT was 16% (95% CI 10%, 22%).
A small proportion of our overall transplant patient
cohort got COVID-19 (1.5%) compared to 9.6% he-
modialysis patients, 4.7% peritoneal dialysis patients,
and 4.7% of waitlisted patients with an in-hospital case
fatality ratio of 31.57%. A German multicenter study of
10,021 patients with COVID-19 admitted to 920 hospi-
tals found an overall mortality of 22% and a 53%
mortality in those requiring mechanical ventilation.20
A UK study of 20,133 patients admitted to 208 hospi-
tals demonstrated an overall mortality of 26%21
compared to the pooled mortality of 24% in our
meta-analyses. Our overall case fatality ratio of 26% is
very similar to the 27% mortality observed in UK data
in renal transplant recipients (NHSBT weekly COVID-
19 reports). Transplant patients had case fatality ra-
tios comparable to that of hemodialysis patients. The
case fatality ratio of waitlisted patients was lower
compared with transplant patients, but this difference
was not statistically significant. Waitlisted patients
tend to be younger and with fewer comorbidities
compared to some of the older transplant patients, and
this may largely explain this difference. Older age was
associated with poor prognosis, with a median age of 71
years for transplant patients who died compared with
59 years for those who survived. This is consistent
with the Spanish series by Perez-Saez et al., whoKidney International Reports (2021) 6, 574–585
M Phanish et al.: COVID-19 in Kidney Transplant CLINICAL RESEARCHreported a hazard ratio of death of 3.1 for patients older
than 60 years.22 We observed 50% mortality of intu-
bated patients, and this compares favorably with the
53% mortality among general medical patients with
COVID-19 requiring invasive mechanical ventilation in
the German study.20 Similarly, Rinaldi et al. found no
difference in survival in transplant patients compared
with the general population.17 All the patients from our
cohort who were discharged home have survived to
date.
It is likely that baseline immunosuppressive burden
plays a role in the prognosis of COVID-19 as it does
with other infections. Our units have a significant
number of patients (approximately 60%-70%) on long-
term dual immunosuppression.7 There was a trend to-
ward higher risk of death in patients on triple immu-
nosuppression, but this did not achieve statistical
significance probably because of the small sample size.
It needs to be seen in larger data sets if patients on
triple immunosuppression are at higher risk of severe
disease from SARS-CoV-2 compared with those on 2
drugs and if mycophenolate mofetil confers higher
risk. We managed all the patients in line with NHS
Blood and Transplant British Transplantation Society
guidelines with immunosuppression reduction as the
main strategy along with supportive medical care
(https://bts.org.uk/information-resources/covid-19-
information/) and recruitment into national clinical
trials. Some of our patients were enrolled into the RE-
COVERY trial and received tocilizumab outside the trial
on clinical grounds, but the numbers are too small to
draw any conclusions on the effectiveness of these
drugs. For current recommendations on the manage-
ment of transplant patients with COVID-19 that include
guidelines on the use of dexamethasone and remdesivir
in transplant patients with COVID-19 pneumonia, the
reader is referred to recent British Transplant Society
(BTS)/UK renal association guidelines. (https://bts.org.
uk/wp-content/uploads/2020/07/Clinical-management-
of-transplants-and-immunosuppression-updated-9th-
July.pdf). We would like to highlight here that some of
the drugs used worldwide for COVID-19 such as azi-
thromycin and lopinavir/ritonavir show significant
interaction with tacrolimus, causing toxicity, and
therefore, should be avoided where possible and, if
used, tacrolimus levels should be monitored closely.
We observed a high percentage of AKI in these pa-
tients (68%) and 6 (31.5%) patients with stage 3 AKI.
In comparison, the pooled proportion of AKI was 50%
and that of stage 3 / RRT-requiring AKI was 16% to
18%. There was significant heterogeneity in studies
reporting AKI as some reported all stages and some
only reported patients requiring RRT. We analyzed
these separately and included stage 3 / RRT requirementKidney International Reports (2021) 6, 574–585in 1 group as this indicates severe AKI. However, it must
be noted that studies that reported patients requiring
RRT only would have excluded patients with stage 3
AKI not needing RRT and, therefore, the true number of
stage 3 AKI in these studies is likely to be higher than
reported. Reassuringly, the AKI recovered in most cases.
Two patients who remained dialysis dependent had
poor baseline kidney function (estimated glomerular
filtration rate<20 ml/min per 1.73 m2), and their kidney
function deteriorated further during their hospital stay.
It is possible that these patients developed rejection on
immunosuppression reduction but we did not have
transplant kidney biopsy results to prove this. On
clinical grounds, we felt that treating COVID-19 pneu-
monia was the priority and, therefore, felt that the risk-
benefit ratio did not favor doing a biopsy. During this
period, we found an AKI risk of 26% in hospitalized
patients with COVID-19 (i.e., 204 of 792 hospitalized
patients in 3 hospitals from South London and Surrey
developed AKI; personal communication). A recent
publication on all hospitalized patients found an AKI in
36.6% of patients and 31.1% had stage 3 AKI23, very
similar to the stage 3 AKI prevalence that we observed in
our transplant cohort.
Following discharge from the hospital, patients were
followed up in a dedicated COVID-19 outpatient setting
for 4 weeks. In one of the 2 hospitals, we performed
repeat SARS-CoV-2 nasal and throat swabs 3-4 weeks
following discharge. All of the 8 patients tested had
cleared the virus, with negative follow-up swab PCR
results. The negative swab enabled us to deisolate these
patients and return them to their normal outpatient
pathway provided they have been free from symptoms
for at least 3 days. The recently published New York
study reported that 8 of 13 hospitalized patients
retested were negative (median retest 29 days).9 Dif-
ference in management of immunosuppression may
account for this difference; we stopped mycophenolate
mofetil in all of our hospitalized patients whereas in
this study 24 of 39 patients (61%) discontinued
mycophenolate mofetil. It needs to be seen if continu-
ation of mycophenolate mofetil in transplant patients
admitted with COVID-19 is associated with more pro-
longed viral shedding.
During the early stages of the pandemic in the
United Kingdom, between February 1, 2020, and March
23, 2020, we performed 19 transplants, among whom 3
patients tested positive for SARS-CoV-2. One patient
had mild illness that was managed at home with regular
outpatient reviews. Two of these 3 patients developed
COVID-19 pneumonia requiring hospitalization. One of
the hospitalized patients had delayed graft function
and rejection requiring methylprednisolone infusions;
he spent 60 days in the intensive care unit with 57 days583
CLINICAL RESEARCH M Phanish et al.: COVID-19 in Kidney Transplantof invasive ventilation. He was successfully discharged
home stable on regular hemodialysis as his graft failed.
A limitation of our study is that we did not systemat-
ically screen all transplant recipients or dialysis pa-
tients at regular intervals. The data presented include
only symptomatic patients who reported to our centers
and tested positive for SARS-CoV-2. Therefore, it is
possible to underestimate the true prevalence of SARS-
CoV-2 infection in our cohort. However, it does capture
all symptomatic infections requiring hospitalization.
It is worth noting that the studies analyzed showed a
case fatality ratio of 22% to 38%, in spite of differences
in management strategies, in particular with regard to
the use of specific pharmacotherapy.2,3,5–19
Our transplant program was suspended on March
23, 2020, because of the increasing number of COVID-
19 patients in South-west London and the unprece-
dented demand on critical care services. Based on our
data analysis, out clinical experience of managing
transplant patients with COVID-19, and the national
guidelines, we reopened our transplant program in the
latter part of June 2020. All the potential recipients
received letters with specific counseling and consent-
ing along the lines of advice given by the NHS Blood
and Transplant (NHSBT) and Organ Donation and
Transplantation UK (https://www.odt.nhs.uk/covid-1
9-advice-for-clinicians/re-opening-of-transplant-pro-
grammes/). These guidelines were used to develop
pathways that include access to “green” theaters, with
dedicated outpatient clinic areas for follow-up and
plans for re- admission into non–COVID-19 wards if
needed.
We have as of this writing (until October 15, 2020)
performed 32 kidney transplants since our reopening.
We have limited donor case selection to lower-risk
donors (i.e., DBD [donation after brainstem death] do-
nors age <60 years, DCD [donation after cardiac death]
donors age <50 years, no significant AKI in the donor
[to minimize the risk of delayed graft function and
prolonged hospital stay], and no extended-criteria do-
nors). The current national policy is to only offer or-
gans from donors who did not die of COVID-19 and
after obtaining negative SARS-CoV-2 PCR test (naso-
pharyngeal swab and endotracheal aspirate). We have
reactivated lower-risk patients who are aged <65
years, body mass index <30 with low to medium car-
diovascular risk, and not expected to require critical
care admission during their inpatient stay. For living-
donor kidney transplants, both the donor and the
recipient are requested to “shield” for 14 days pre-
transplant with SARS-CoV-2 testing (nasal and throat
swabs for PCR) at 14 and 2 days prior to surgery. We
intend to expand donor and recipient acceptance
criteria in a phased manner.584In conclusion, from our large cohort of transplant
patients, a small proportion got COVID-19, with the
proportion of infection significantly lower than that of
waitlisted patients and those on dialysis. The overall
case fatality ratio (26%) was comparable to that of the
dialysis cohort and patients on waitlist. Thirty-one
percent required intubation and ventilation, of whom
50% died. Within our entire cohort, a significantly
lower proportion of transplant patients died of COVID-
19 compared with hemodialysis and peritoneal dialysis
patients. The case fatality ratio of hospitalized trans-
plant patients with COVID-19 was 31.57%. The older
age and severity of illness were associated with mor-
tality. We observed a high proportion of AKI (68%),
but the majority recovered. Meta-analysis of 16 studies
including ours revealed pooled case fatality ratio of
24% for hospitalized patients, pooled AKI proportion
of 50%, and pooled proportion of severe AKI of 16% to
18%. We have successfully restarted our transplant
program with defined donor and recipient criteria to
minimize the risk and optimize the outcomes.DISCLOSURES
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